Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Chemo brain' cognitive issues linked to poor lymphatic-system drainage

2.

Study finds 1 in 12 patients labeled as having 'benign' results actually had high-risk prostate cancer

3.

Novel biomarkers may improve diagnosis of gallbladder cancer

4.

More evidence links physical activity with improved cancer survival

5.

Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot